Diabetic Nephropathy: Rising prevalence of chronic kidney diseases drives the growth of the global market

Market Research Future (MRFR) has published a cooked research report on the “Diabetic Nephropathy Market” that contains information from 2018 to 2030. The Diabetic Nephropathy Market is estimated to register a CAGR of 6.20% during the forecast period of 2023 to 2030.

Diabetic Nephropathy Market Highlights

The global Diabetic Nephropathy Market is accounted to register a CAGR of 6.20% during the forecast period and is estimated to reach USD 3.43 billion by 2030.

Diabetic nephropathy, also known as diabetic kidney disease, is a progressive kidney disease that occurs as a complication of diabetes. It is a leading cause of end-stage renal disease (ESRD) worldwide. The global market for diabetic nephropathy encompasses various diagnostic and therapeutic products and services aimed at managing the condition and improving patient outcomes. The global diabetic nephropathy market has been experiencing steady growth over the years due to the increasing prevalence of diabetes and the rising awareness of diabetic kidney disease.

Key Players:

MRFR recognizes the following companies as the key players in the global Diabetic Nephropathy Market — Novartis AG (Switzerland), Merck & Co., Inc. (US), Abbott Laboratories (US), Sanofi (France), Eli Lilly and Company (US), Reata Pharmaceuticals, Inc. (US), Bayer AG (Germany), AbbVie, Inc. (US), AstraZeneca (UK), Mitsubishi Tanabe Pharma Corporation (Japan)

Segment Analysis

The global Diabetic Nephropathy Market has been segmented based Diagnosis, Treatment, and End User.

The diabetic nephropathy market segmentation, based on diagnosis, includes blood test, urine tests, imaging test, renal function testing, and kidney biopsy. The blood test segment held the majority share in 2022 in respect to the diabetic nephropathy market revenue. This is primarily owing to the rising prevalence of patients suffering from diabetes. Therefore, increasing chronic diseases such as obesity, and diabetes, have increased the demand for blood tests.

The diabetic nephropathy market segmentation, based on treatment, includes medication, kidney dialysis, and transplant. The medication segment dominated the market in 2022 in respect to the diabetic nephropathy market. This is attributed to the increasing number of chronic diseases such as obesity, diabetes, and other chronic illness that have increased the demand for medications.

The diabetic nephropathy market segmentation, based on end user includes hospital & clinics, surgical centers, and others. The hospital & clinics held the largest market share in 2022 with respect to the diabetic nephropathy market revenue. Hospital & clinics have the highest market share as chronic kidney disease has become common across the globe and people suffering from chronic kidney disease have an increased risk of health complications. Based on one of the research articles from PLOS Medicine, adults suffering from chronic kidney disease have a higher hospitalization rate than the general population getting hospitalized. This eventually increases the use of drugs for treatment from hospital & clinics.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Diabetic Nephropathy Market Research Report

Regional Analysis

The global Diabetic Nephropathy Market , based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World . North America diabetic nephropathy held the largest market share in 2022. This is attributed to the increase in the prevalence of diabetic nephropathy, health care infrastructure, and increased use of combination drugs, as well as an increase in diabetic patients’ awareness of diabetic nephropathy.

Europe diabetic nephropathy market accounts for the second-largest market share due to the rising government and pharmaceutical organization efforts to raise awareness of kidney disease as well as the existence of generic manufacturers are also boosting the market growth. Further, the Germany diabetic nephropathy market held the largest market share, and the UK diabetic nephropathy market was the fastest-growing market in the European region.

The Asia-Pacific Diabetic Nephropathy market is expected to grow at a significant growth rate during the forecast period. This is due to the increased healthcare spending, increased market awareness of new diabetic drugs, and increase in the number of hospitals are factors expected to boost the market over the forecast period. Moreover, China diabetic nephropathy market held the largest market share, and the India diabetic nephropathy market was the fastest-growing market in the Asia-Pacific region. Hence, Asia-Pacific is anticipated to register the highest growth rate over the forecast period from 2023–2030.

Key Findings of the Study

• North America diabetic nephropathy held the largest market share in 2022. This is attributed to the increase in the prevalence of diabetic nephropathy, health care infrastructure, and increased use of combination drugs, as well as an increase in diabetic patients’ awareness of diabetic nephropathy.


• The diabetic nephropathy market segmentation, based on diagnosis, includes blood test, urine tests, imaging test, renal function testing, and kidney biopsy.


• Novartis AG (Switzerland), Merck & Co., Inc. (US), Abbott Laboratories (US), Sanofi (France), Eli Lilly and Company (US), Reata Pharmaceuticals, Inc. (US), Bayer AG (Germany), AbbVie, Inc. (US), AstraZeneca (UK), Mitsubishi Tanabe Pharma Corporation (Japan)